114 related articles for article (PubMed ID: 37075870)
1. Aromatic Rings as Molecular Determinants for the Molecular Recognition of Protein Kinase Inhibitors.
Zhu Y; Alqahtani S; Hu X
Molecules; 2021 Mar; 26(6):. PubMed ID: 33810025
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive review of protein kinase inhibitors for cancer therapy.
Kannaiyan R; Mahadevan D
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1249-1270. PubMed ID: 30259761
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015.
O Brien Z; Moghaddam MF
Curr Med Chem; 2017; 24(29):3159-3184. PubMed ID: 28545370
[TBL] [Abstract][Full Text] [Related]
4. Predictive modeling of skin permeability for molecules: Investigating FDA-approved drug permeability with various AI algorithms.
Abdallah RM; Hasan HE; Hammad A
PLOS Digit Health; 2024 Apr; 3(4):e0000483. PubMed ID: 38568888
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical Profiling and Comparison of Research Antiplasmodials and Advanced Stage Antimalarials with Oral Drugs.
Bhanot A; Sundriyal S
ACS Omega; 2021 Mar; 6(9):6424-6437. PubMed ID: 33718733
[TBL] [Abstract][Full Text] [Related]
6. Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors.
Bellantoni AJ; Wagner LM
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298746
[TBL] [Abstract][Full Text] [Related]
7. Softening the Rule of Five--where to draw the line?
Petit J; Meurice N; Kaiser C; Maggiora G
Bioorg Med Chem; 2012 Sep; 20(18):5343-51. PubMed ID: 22222160
[TBL] [Abstract][Full Text] [Related]
8. Structure-property Relationships Reported for the New Drugs Approved in 2023.
Choi K
Mini Rev Med Chem; 2024 Apr; ():. PubMed ID: 38676492
[TBL] [Abstract][Full Text] [Related]
9. A simple approach discriminating cardio-safe drugs from toxic ones.
Falah M; Nassar T; Rayan A
Bioinformation; 2009 Jun; 3(9):389-93. PubMed ID: 19759813
[TBL] [Abstract][Full Text] [Related]
10. CDK Inhibitors and FDA: Approved and Orphan.
Cicenas J; Simkus J
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672637
[TBL] [Abstract][Full Text] [Related]
11. Unlocking Potential and Limits of Kinase Inhibitors: The Highway to Enhanced Cancer Targeted Therapy.
Musumeci F; Schenone S
Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794286
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics approach for structure modeling, vaccine design, and molecular docking of Brucella candidate proteins BvrR, OMP25, and OMP31.
Elrashedy A; Nayel M; Salama A; Salama MM; Hasan ME
Sci Rep; 2024 May; 14(1):11951. PubMed ID: 38789443
[TBL] [Abstract][Full Text] [Related]
13. Investigating the Mechanistic of Danhong Injection in Brain Damage Caused by Cardiac I/R Injury via Bioinformatics, Computer Simulation, and Experimental Validation.
Wang J; Guo Y; Zhou H; Hua Y; Wan H; Yang J
ACS Omega; 2024 Apr; 9(16):18341-18357. PubMed ID: 38680343
[TBL] [Abstract][Full Text] [Related]
14. Identification of new pharmacophore against SARS-CoV-2 spike protein by multi-fold computational and biochemical techniques.
Ullah A; Ullah S; Halim SA; Waqas M; Ali B; Ataya FS; El-Sabbagh NM; Batiha GE; Avula SK; Csuk R; Khan A; Al-Harrasi A
Sci Rep; 2024 Feb; 14(1):3590. PubMed ID: 38351259
[TBL] [Abstract][Full Text] [Related]
15. The allosteric mechanism of mTOR activation can inform bitopic inhibitor optimization.
Liu Y; Zhang M; Jang H; Nussinov R
Chem Sci; 2024 Jan; 15(3):1003-1017. PubMed ID: 38239681
[TBL] [Abstract][Full Text] [Related]
16. Network pharmacology combined with molecular docking and experimental validation to explore the potential mechanism of
Wei W; Wu S; Zhou C; Chen T; Zhu J; Feng S; Zhan X; Liu C
Ann Med; 2023; 55(2):2287193. PubMed ID: 38019769
[TBL] [Abstract][Full Text] [Related]
17. Rule of five violations among the FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2023 May; 191():106774. PubMed ID: 37075870
[TBL] [Abstract][Full Text] [Related]
18. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract][Full Text] [Related]
19. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
